ADVANCE Study Ralinepag (IP receptor agonist)
NCE / Novel Biologics therapeutic platform
ADVANCE Study Ralinepag (IP receptor agonist)
ADVANCE OUTCOMES is a Phase 3, randomized, placebo-controlled, double-blind, multicenter study to evaluate the efficacy of ralinepag in subjects with pulmonary arterial hypertension (PAH) by evaluating ralinepag’s impact on time to clinical worsening in patients with PAH.
Ralinepag is a novel, once daily IP receptor agonist undergoing Phase 3 studies for PAH. Ralinepag has demonstrated superiority and improved pharmacology over selexipag in nonclinical studies and proof of concept in a Phase 2 clinical trial in PAH.
Ralinepag is a development-stage product not approved for sale in any jurisdiction.